ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Revance Therapeutics Inc

Revance Therapeutics Inc (RVNC)

3.92
0.19
(5.09%)
마감 04 12월 6:00AM
3.92
-0.005
(-0.13%)
시간외 거래: 9:21AM

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
3.92
매수가
3.92
매도가
4.13
거래량
1,554,382
3.735 일간 변동폭 4.12
2.30 52주 범위 9.745
market_cap
전일 종가
3.73
개장가
3.90
최근 거래 시간
24
@
3.93
마지막 거래 시간
재정 규모
US$ 6,026,304
VWAP
3.877
평균 볼륨(3m)
2,943,225
발행 주식
104,902,388
배당수익률
-
주가수익률
-1.27
주당순이익(EPS)
-3.09
매출
234.04M
순이익
-323.99M

Revance Therapeutics Inc 정보

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD pl... Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Revance Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker RVNC. The last closing price for Revance Therapeutics was US$3.73. Over the last year, Revance Therapeutics shares have traded in a share price range of US$ 2.30 to US$ 9.745.

Revance Therapeutics currently has 104,902,388 shares in issue. The market capitalisation of Revance Therapeutics is US$391.29 million. Revance Therapeutics has a price to earnings ratio (PE ratio) of -1.27.

RVNC 최신 뉴스

Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update

- On August 11, 2024, Revance and Crown Laboratories, Inc. entered into a merger agreement. As a result of discussions between the Revance and Teoxane, Crown and Revance agreed to extend the...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.05-1.259445843833.974.213.5519277273.79788503CS
4-1.88-32.41379310345.85.963.3626358603.9523736CS
12-2.65-40.33485540336.576.593.3629432255.2657592CS
26134.24657534252.926.652.333446395.38105903CS
52-3.29-45.63106796127.219.7452.325937345.33554811CS
156-10.9-73.549257759814.8237.982.3170656813.25879521CS
260-15.85-80.171977744119.7737.982.3128671915.17255575CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ZJKZJK Industrial Company Ltd
US$ 17.185
(171.06%)
28.21M
CTNTCheetah Net Supply Chain Service Inc
US$ 4.81
(157.22%)
113.16M
ORISOriental Rise Holdings Ltd
US$ 11.11
(69.10%)
1.47M
JYDJayud Global Logistics Ltd
US$ 1.1299
(68.62%)
10.8M
GWAVGreenwave Technology Solutions Inc
US$ 0.6078
(66.52%)
512.32M
REVBRevelation Biosciences Inc
US$ 0.504151
(-46.93%)
6.04M
OMEXOdyssey Marine Exploration Inc
US$ 0.4201
(-43.63%)
4.83M
RITRReitar Logtech Holdings Ltd
US$ 2.68
(-38.39%)
1.25M
XCURExicure Inc
US$ 14.05
(-37.00%)
428.68k
AGFYAgrify Corporation
US$ 32.72
(-36.69%)
283.41k
GWAVGreenwave Technology Solutions Inc
US$ 0.6078
(66.52%)
512.26M
SMCISuper Micro Computer Inc
US$ 40.21
(-4.26%)
200.61M
NVDANVIDIA Corporation
US$ 140.26
(1.18%)
162.81M
INTCIntel Corporation
US$ 22.47
(-6.10%)
135.91M
CHRSCoherus BioSciences Inc
US$ 1.7001
(24.09%)
113.52M

RVNC Discussion

게시물 보기
MeteoricChimera43 MeteoricChimera43 7 시간 전
And all positions are being held at 4% average if all shares, keeping them all just under the 5% ownership filing rule, except BlackRock, who also just happens to have a $3.88 average share price, but they own 9% of all outstanding shares. Strange stuff going on
👍️ 1
MeteoricChimera43 MeteoricChimera43 8 시간 전
I can’t paste photos on here for some reason, but look at Sage Tracker for Institutional positions and you’ll see them all.
👍️0
MeteoricChimera43 MeteoricChimera43 8 시간 전
Can anyone explain why there was like 50,000,000 new Institutional positions positions taken recently and ALL closed at $3.88 per share. No way that’s even possible unless someone planned it.
👍️0
alertmeipp alertmeipp 10 시간 전
What are the chances that the delay is due to a new buyer want to join force with Crown, like TEOXANE
🤔 1
MeteoricChimera43 MeteoricChimera43 11 시간 전
100% agree and they had a line of credit that they never used in 2023
👍️0
alertmeipp alertmeipp 12 시간 전
Therapeutic alone could bring in 100s of millions od sales over time and Daxxify has clear advantage there.

Revance should just raise additional capital to keep pushing forward rather than giving up all upside hy selling out at 6 bucks.
👍️ 3
Biowatch Biowatch 13 시간 전
Dew is stating his opinion, not giving fiduciary advice. Plenty of people have disagreed with Dew on numerous occasions.

Dew can be wrong, as all of us can, especially in biotech. I admit, most biotechs go up after FDA approval of their main product, but RVNC has been the exception, not the rule.

You are not paying Dew for their advice. You don’t even pay to post on iHub.

I publicly stated that I sold all my RVNC, at a substantial loss, within days of their initial announcement of the $6.66 buyout. I’m glad I did. Other people sold when the stock was at $36, oh so long ago, and said so, while others hold on, hoping for better days. That’s what makes a market.

If you only listen to what Dew says, and not others, that’s on you.

If you want someone to blame, look to Foley and RVNC management. It shouldn’t take um-teem times to close a sale and take the company private, leaving all the investors in a publicly traded company twisting in the wind.
👍️ 5
vinmantoo vinmantoo 14 시간 전
It says milestone payments (plural), which I take to mean separate milestone payments for each of the two indications.

Thanks Dew. It would be nice if Foley had thought about mentioning this.
👍️ 1
DewDiligence DewDiligence 14 시간 전
Yes, RVNC is due a (probably modest) milestone payment from Fosun Pharma for China’s approval of Daxxify in CD. From RVNC’s 2023 10-K (page 11):

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000147929024000038/rvnc-20231231.htm In April and July 2023, the NMPA accepted Fosun’s BLA for DaxibotulinumtoxinA for Injection for the improvement of glabellar lines and treatment of cervical dystonia, respectively. The anticipated approvals for both indications are expected in 2024. We are entitled to receive additional milestone payments from Fosun upon approval of DaxibotulinumtoxinA for Injection in China… It says milestone payments (plural), which I take to mean separate milestone payments for each of the two indications.
👍️ 2
vinmantoo vinmantoo 14 시간 전
Meanwhile, China approved Daxxify for cervical dystonia.

Is there any milestone for this approval? I wonder if Teoxane is getting mad that Foley undervalued the potential money from Daxxify sales in China in accepting the current bid of $6.66 and they are pushing for either a higher price or for the deal to end.

Stocksrising, thanks for the post that was more complete than mine on this topic. I posted mine before reading yours. We are on the same page.
👍️ 2 😉 2
MeteoricChimera43 MeteoricChimera43 15 시간 전
cervical dystonia is not the only medical condition they use DAXXIFY for. Any condition like Pudendal neuralgia or any nerve condition that creates spasms it’s highly recommended and being used more and more, because it last twice as long as Botox, which they’ve been using for years for the same purposes, and on an in very increased basis year over year. This may not be a huge income stream in the short term, but Revance and other know the potential to be huge.
👍️ 3
alertmeipp alertmeipp 16 시간 전
2 days extension now, its like Xmas count down
👍️ 1
stocksrising stocksrising 16 시간 전
As many of us speculated, Price paid adjustments and teoxone relationship along with breakup fee’s are prob holding up Tender but could this Fosun approval move the needle??
Don’t know if ~70k Chinese market will mean much, but this brings more markets opened for Crown if successful and mr. market likes this release..I’m sure market also likes a 2 day extension( perhaps final , lol)


From Bing AI:
How many people in China have cervical dystonia?
Copilot—

Cervical dystonia, also known as spasmodic torticollis, is a neurological disorder characterized by involuntary muscle contractions in the neck, leading to abnormal movements and postures of the head and neck. In China, the prevalence of cervical dystonia is estimated to be around 4.98 per 100,000 people 1 2. This means that in a population of approximately 1.4 billion, there could be around 69,720 individuals affected by this condition.
👍️ 1
DewDiligence DewDiligence 17 시간 전
RVNC tender delayed until 12/5/24 (or later):

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000114036124048244/ef20039450_8k.htm

Meanwhile, China approved Daxxify for cervical dystonia.
👍️ 4
alertmeipp alertmeipp 1 일 전
For the nth time, hope we can move on from Crown and Foley fired.
👍️ 1
Emannow Emannow 1 일 전
I stated many times that Foley was a total idiot! Many Allergan executives told me they would never join or be part of a company that Foley runs! The guy is a narcissist and total train wreck!

Teoxane is the only company that would love to take over Revance! I hope Teoxane gets the chance to showcase Daxi and kicks Foley to the curb!!!
👍️ 5
vinmantoo vinmantoo 2 일 전
I have never knowingly spread any false information of any nature whatsoever.

No, you just accused/lied that others who had a different opinion than you of knowingly spread false information. I find it despicable.

If the permabulls had listened to what I have said on this board, they would’ve sold their shares at much higher prices, and been a lot wealthier than they are today. If they (you) still felt that the company is a worthwhile risk, they could’ve used some of the profits that they would’ve taken to buy practically any number of shares with money that they felt like throwing in the garbage can.

What a pathetic little self-serving screed! So if you were such a genius you must have shorted RVNC and made a fortune, right?

Rather than repeatedly attack and demean others who had a different view of RVNC's prospects, why don't you use your financial genius and give of 4 or 5 excellent biotech risks where we can invest our hard earned money? It should be child's play for such a self-proclaimed financial guru as yourself.
👍️ 1
alertmeipp alertmeipp 2 일 전
You dont have names. I knew it. ;)
👍️ 1
IanFromSI IanFromSI 2 일 전
Why would I share names with you?

All you’ve done is ignore me and to attack me.
… And lose money while doing so.
👍️0
alertmeipp alertmeipp 2 일 전
Share some names

Every board all i see u is bashing
👍️ 1
IanFromSI IanFromSI 2 일 전
I have never knowingly spread any false information of any nature whatsoever.

If the permabulls had listened to what I have said on this board, they would’ve sold their shares at much higher prices, and been a lot wealthier than they are today. If they (you) still felt that the company is a worthwhile risk, they could’ve used some of the profits that they would’ve taken to buy practically any number of shares with money that they felt like throwing in the garbage can.

There are numerous biotechs which offer substantial opportunities for growth. I failed to understand that the permabulls would continue to stubbornly remain addicted to the belief that this company had the best product and therefore was guaranteed to have a fabulous stock price even as bankruptcy became more imminent and more probable.

But I have come to the conclusion that anyone who wants to stick with that belief, deserves to lose their money. There’s nothing more that I can say that will be accepted as a needed insight or warning.

If you wish to continue to ignore me, it’s your money. Have at it!

Failing further attacks on me, this is my last post on this subject. Hopefully.!!!
👍️ 1 😂 1
alertmeipp alertmeipp 2 일 전
IanFromSI, question, why would someone continue to spread false info and then pretend to care about people losing money here? Why?

I am sure you wont think i am talking about you!
👍️ 1
IanFromSI IanFromSI 2 일 전
The message I’m replying to was a response to Dew D in which he promoted keeping your RVNC shares.

I was surprised when he:

- didn’t respond to my message, and instead,
- Deleted his post rather than mine.

So I did a little digging. Here’s the law in Canada.

=====================================
Promoting a stock that is nearing bankruptcy can be considered a criminal offense if it involves fraudulent misrepresentation or deceit.

If the promoter knowingly makes false statements to inflate the stock price and then sells their shares, they can be charged with securities fraud.

This is especially true if the actions influence the market price of the stock.
=====================================

I think the US has either the same or very similar set of laws in its criminal code.
👍️ 2 🤣 1
vinmantoo vinmantoo 3 일 전
Nonetheless, we should’ve recognized long ago that Crown no longer wishes to purchase RVNC at $6.66, and that RVNC has not been able to find another interested buyer yet.

Maybe, maybe not. You keep trying to tell us you know what will happen or why it is happening when nobody knows. What has been going on is extremely unusual if not unprecedented. I sure as hell haven't seen anything like it. I can spew out a guess that Teoxane wants a higher buyout price. Crown really wants to buy RNVC so is negotiating how much more they will have to pay to satisfy Teoxane. My guess is as worthless as yours.
👍️ 2
alertmeipp alertmeipp 3 일 전
Foley is just the worst CEO ever - really hope to get over Crown soon one way or another. Can't believe he can't even close a lowball deal done properly.
Crown should see tons of upside after they had deal with Foley.
👍️ 2
Jab44 Jab44 4 일 전
For those who didn’t execute their position at the $6.60 level I feel bad for you. Personally I lost well over 300k with Foley and his poor decision making and incompetence. After all the missteps, when crown agreed to the deal I reluctantly sold knowing that the company was worth more. For those who suggested shareholders were better to wait until the deal closed they were dead wrong. I hope for the shareholders who stuck with the likes of Angus Russell and Foley I truly hope you receive at least $5.50 . From my investing experience you are in uncharted waters.
Best of luck to all of you now and in the future..
👍️ 4
IanFromSI IanFromSI 4 일 전
Nonetheless, we should’ve recognized long ago that Crown no longer wishes to purchase RVNC at $6.66, and that RVNC has not been able to find another interested buyer yet.
👍️ 1
mouton29 mouton29 4 일 전
In the last 8K, I believe the word price got changed to “offer” price.

That may be your belief, but three minutes of looking at the sec website confirms that you are mistaken.

8K from Nov 26

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000114036124047831/ef20039245_8k.htm

he Company’s ongoing discussions with the Buyer Parties could result in further delays to the commencement or consummation of the Offer, or in the Company or the Buyer Parties seeking remedies in accordance with, and modifications to, the terms of the Merger Agreement, including offer price.

8K from Nov 19

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000114036124047293/ef20038831_8k.htm

The Company’s ongoing discussions with the Buyer Parties could result in further delays to the commencement or consummation of the Offer, or in the Company or the Buyer Parties seeking remedies in accordance with, and modifications to, the terms of the Merger Agreement, including offer price.

8K from Nov 12

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000114036124045956/ef20038428_8k.htm

The Company’s ongoing discussions with the Buyer Parties could result in further delays to the commencement or consummation of the Offer, or in the Company or the Buyer Parties seeking remedies in accordance with, and modifications to, the terms of the Merger Agreement, including offer price.

8K from Nov 1

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000114036124044892/ef20038055_8k.htm

The Company’s ongoing discussions with the Buyer Parties could result in further delays to the commencement or consummation of the Offer, or in the Company or the Buyer Parties seeking remedies in accordance with, and modifications to, the terms of the Merger Agreement, including offer price.
👍️ 4
IanFromSI IanFromSI 4 일 전
In the last 8K, I believe the word price got changed to “offer” price. I. E. Ambiguity has been removed, and Crown probably doesn’t wanna buy RVNC and
almost certainly is no longer willing to pay $6.66.

I’ve never seen a situation like this before, so I have no idea if any precedents would allow Revance to accept a lower offer and not be sued by the arbitrageurs and possibly others. …. Like Teoxane. I doubt that any other shareholders have any recourse.

I can’t imagine any path that leads to a happy ending for existing shareholders.
👍️ 4
stocksrising stocksrising 5 일 전
I can deal with that, either way...then reshuffle C-ste, have a few board members resign and refocus on Sales/Marketing but first secure financing from various sources if possible*.. stock goes sub $2( for a qtr or 2), and slowly accumulate for a 2026 payoff...the product works( as you and many say-including my GF and her injector, others)...lets see what happens next week( or the , or the next, and so on)...Happy Holidays
👍️ 1
vinmantoo vinmantoo 5 일 전
Honestly, been around ‘the street’ for several decades, personally participated in 2 reverse merge’s( this isn’t exactly that, but) and have no clue what could be the weekly holdups!!

They decided they wanted to finish their Christmas shopping before finalizing the deal. This way their minds wouldn't be distracted by worrying about what to get their spouse.
👍️0
alertmeipp alertmeipp 5 일 전
if that's what they have been discussing about, then management should have hosted a call for Q3 to talk up the company as an ongoing entity?
👍️0
DewDiligence DewDiligence 5 일 전
The lingering disagreement may be about which party pays the break-up fee.
👍 1
alertmeipp alertmeipp 5 일 전
So now they might tender during the holiday seasons
👍️0
alertmeipp alertmeipp 5 일 전
Still think the most likely scenario is they will go through with reduced price. At this point, put is just too expensive for me.
👍️ 1
DewDiligence DewDiligence 5 일 전
RVNC tender delayed until 12/3/24 (or later):

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000114036124048023/ef20039354_8k.htm

Other than the date, the language in the post I’m replying to is identical to the 8-K filing on 11/26/24.
👍️ 1
stocksrising stocksrising 5 일 전
Honestly, been around ‘the street’ for several decades, personally participated in 2 reverse merge’s( this isn’t exactly that, but) and have no clue what could be the weekly holdups!! I mean, if they are negotiating ‘several aspects of transaction’, why not go bi-monthly/monthly, etc…
So, I’m buying downside puts for protection, but
Holding current( reduced) positions since ‘deal’ announced…now we wait until next week, enjoy the holiday shopping:)
👍️0
alertmeipp alertmeipp 5 일 전
What are they even discussing at this point?
Crown is playing game or what
👍️0
stocksrising stocksrising 5 일 전
extended to 12/3 :)

Due to the ongoing discussions between the Company and Crown, the Company and the Buyer Parties agreed on November 29, 2024 to further extend the date by which Merger Sub is obligated to commence the Offer pursuant to the previously announced Merger Agreement, to December 3, 2024 or such other date as may be mutually agreed to between the Company and the Buyer Parties. The Company’s ongoing discussions with the Buyer Parties could result in further delays to the commencement or consummation of the Offer, or in the Company or the Buyer Parties seeking remedies in accordance with, and modifications to, the terms of the Merger Agreement, including offer price.
👍️ 1
stocksrising stocksrising 7 일 전
Ahhh, the good ole’ days when we could all talk about the benefits of Daxxy vs. competition ( and the claims and marketing on social media) …if deal closes, all a moot point, but if not, Revance could really take advantage of others missteps( assuming new leadership @ helm)

https://www.fiercepharma.com/marketing/fda-slams-merz-over-misleading-instagram-ad-botox-rival
👍️ 2
vinmantoo vinmantoo 1 주 전
Extended to Nov 29… this Friday.

So are they are going to make the deal on Wednesday, work over Thanksgiving to make the deal on Friday or postpone until Christmas Eve? You decide.
👍️ 1 😉 1
alertmeipp alertmeipp 1 주 전
Looks like Foley has secured his long weekend
👍️0
DewDiligence DewDiligence 1 주 전
Tender extended until 11/29/24 (or later):

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479290/000114036124047831/ef20039245_8k.htm

Other than the date, the language in the post I’m replying to is identical to the 8-K filing one week ago.
👍️ 4
stocksrising stocksrising 1 주 전
Maybe Fooley grew a soul and didn’t want to break hearts until after Thanksgiving, lmao…maybe a 5pm, Black Friday 8k???
👍️0
stocksrising stocksrising 1 주 전
Item 8.01 Other Events.
As previously disclosed in the Company's Current Report on Form 8-K filed on November 19, 2024, Revance Therapeutics, Inc. (the "Company" or "Revance"), Crown Laboratories, Inc. ("Crown") and Reba Merger Sub, Inc.
("Merger Sub," and together with Crown, the "Buyer Parties") agreed on November 19, 2024 to further extend the date by which Merger Sub is obligated to commence the tender offer for all of the outstanding shares of common stock of the Company (the "Offer") pursuant to the previously announced Agreement and Plan of Merger, dated as of August 11, 2024, by and among the Buyer Parties and the Company (the "Merger Agreement"), to November 26, 2024 or such other date as may be mutually agreed to between the Company and the Buyer Parties. Due to the ongoing discussions between the Company and Crown, the Company and the Buyer Parties agreed on November 26, 2024 to further extend the date by which Merger Sub is obligated to commence the Offer pursuant to the previously announced Merger Agreement, to November 29, 2024 or such other date as may be mutually agreed to between the Company and the Buyer Parties. The Company's ongoing discussions with the Buyer Parties could result in further delays to the commencement or consummation of the Offer, or in the Company or the Buyer Parties seeking remedies in accordance with, and modifications to, the terms of the Merger Agreement, including offer price.
A copy of the waiver to the Merger Agreement relating to the extension is attached as Exhibit 99.1 to this Current
Report on Form 8-K
👍️0
alertmeipp alertmeipp 1 주 전
Extended to Nov 29… this Friday.
👍️0
alertmeipp alertmeipp 1 주 전
Another day, another extension?? Or we can all move on from Crown?
👍️ 1
alertmeipp alertmeipp 1 주 전
I know, you are a nice guy to take Ian seriously lol
👍️ 1 😀 1
vinmantoo vinmantoo 1 주 전
Well if the deal is comsumed, the company would be gone in next few months.

I was talking about if the deal didn't go through because that is what it seemed to me that Ian was referring to in his dire prediction.
👍️0
alertmeipp alertmeipp 2 주 전
Well if the deal is comsumed, the company would be gone in next few months. Then the “experts” will be correct
👍️ 1

최근 히스토리

Delayed Upgrade Clock